N-Acetyltransferase 2 (NAT2) Genotype and Colorectal Carcinoma: Risk Variability According to Tumour Site?

References

• Moller-Jensen O, Estève J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990;26:1167–256.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon E, Kern S, et al. Allelotype of colorectal carcinomas. Science 1989;244:207–12.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Nicolaides NC, Wei Y-F, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263: 1625–9.
   Google Scholar
• Potter JD Food, nutrition and the prevention of cancer: a global perspective. Edited by World Cancer Research Fund & American Institute for Cancer Research. Washington DC 1997. p. 216–51.
   Google Scholar
• Wakabayashi K, Nagao M, Esumi H, Sugimura T. Food-derived mutagens and carcinogens. Cancer Res 1992;52:2092S–8S.
   Google Scholar
• Skog K. Cooking procedures and food mutagens: a literature review. Food Chem Toxicol 1993;31:655–75.
   PubMed Web of Science ®Google Scholar
• De Stefani E, Boffeta P, Mendiharsu M, Carzoglio J, Deneo-Pellegrini H. Dietary nitrosamines, heterocyclic amines, and risk of gastric cancer: a case-control study in Uruguay. Nutr Cancer 1998;30:158–62.
   Google Scholar
• Jägerstad M, Skog K, Grivas S, Olsson K. Formation of heterocyclic amines using model systems. Mutat Res 1991;259:219–33.
   PubMed Web of Science ®Google Scholar
• Stillwell WG, Kidd LC, Wishnok JS, Tannembaum SR, Sinha R. Urinary excretion of unmetabolized and phase II conjugates of 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine and 2- amino-3,8-dimethylimidazol[4,5-f]quinoxaline in humans: relationship to cytochrome P4501A2 and N-acetyltransferase activity. Cancer Res 1997;57: 3457–64.
   Google Scholar
• Gooderham NJ, Murray S, Lynch AM, et al. Assessing human risk to heterocyclic amines. Mutat Res 1997;376:53–60.
   PubMed Web of Science ®Google Scholar
• Liu Y, Levy GN. Activation of heterocyclic amines by combination of prostagladin H synthase-1 and -2 with N- acetyltransferase 1 and 2. Cancer Lett 1998;13:115–23.
   Web of Science ®Google Scholar
• Evans DAP. N-acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992. p. 95–178.
   Google Scholar
• Agúndez JAG, Olivera M, Ladero JM, et al. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996;6: 501–12.
   Google Scholar
• Lang NP. Acetylation as an indicator of risk. Environ Health Perspect 1997;105 Suppl 4:763–6.
   PubMed Web of Science ®Google Scholar
• Hickman D, Pope J, Patil SD, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998;42:402–9.
   PubMed Web of Science ®Google Scholar
• Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 1997;376:153–60.
   PubMed Web of Science ®Google Scholar
• Ilett KF, Ingram DM, Carpenter DS, et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 1994;47:914–7.
   PubMed Web of Science ®Google Scholar
• Lang NP, Chu DZ, Hunter CF, et al. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986; 121:1259–61.
   PubMed Web of Science ®Google Scholar
• Ilett KF, David BM, Detchon P, Kastleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987;47:1466–9.
   PubMed Web of Science ®Google Scholar
• Ladero JM, González JF, Benítez et al. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991;51:549–55.
   PubMed Web of Science ®Google Scholar
• Spigelman AD, Farmer KC, Oliver S, et al. Caffeine phenotyping of cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis. Gut 1995;36:251–4.
   PubMed Web of Science ®Google Scholar
• Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998;19:37–41.
   PubMed Web of Science ®Google Scholar
• Hubbard AL, Harrison DJ, Moyes C, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997;41: 229–34.
   PubMed Web of Science ®Google Scholar
• Hardingham JE, Butler WJ, Roder D, et al. Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 1998; 42:669–72.
   PubMed Web of Science ®Google Scholar
• Shibuta K, Nakashima T, Abe M, et al. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994;74:3108–12.
   PubMed Web of Science ®Google Scholar
• Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the arylamine N- acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994;56:202–9.
   PubMed Web of Science ®Google Scholar
• Agúndez JAG, Olivera M, Martínez C, Ladero JM, Benítez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996;6: 423–8.
   Google Scholar
• Martínez C, Agúndez JAG, Olivera M, Martin R, Ladero JM, Banítez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995;5:207–14.
   PubMedGoogle Scholar
• Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N- acetyltransferases. Pharmacogenetics 1995;5:1–17.
   PubMedGoogle Scholar
• Butler MA, Iwasaki M, Guenguerich FP, Kadlubar FH. Human cytochrome P-450PA (p-4501A2), the phenacetin-O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696–700.
   PubMed Web of Science ®Google Scholar
• Nussbaum M, Fiala ES, Kulkarni B, El-Bayoumy ES, Weisburger JH. In vivo metabolism of 3,2′-dimethyl-4-amino- biphenyl (DMAB) bearing on its organotropism in the Syrian golden hamster and the rat. Environ Health Perspec 1983;49: 223–31.
   Google Scholar
• Katoh T, Nagata N, Kuroda Y, et al. Glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and rectal adenocarcinoma. Carcinogenesis 1996;17:1855–9.
   PubMed Web of Science ®Google Scholar
• Deakin M, Elder J, Hendrickse C, et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881–4.
   PubMed Web of Science ®Google Scholar
• Spigelman AD, Nugent KP, Penna C, Foulds S, Phillips RK. Glutathione S-transferase Mu phenotype in patients with familial adenomatous polyposis and in unaffected controls. Cancer Detect Prev 1994;18:253–8.
   Google Scholar
• Feng Y, Wagner RJ, Fretland A, et al. Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic syriam hamsters administered 3,2′-dimethyl-4-aminobiphenyl. Cancer Res 1996;56:527–31.
   PubMed Web of Science ®Google Scholar
• Oda Y, Tanaka M, Nakanishi I. Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferases in human colorectal carcinomas. Carcinogenesis 1994;15:1365–9.
   Google Scholar
• Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997;18: 1351–4.
   PubMed Web of Science ®Google Scholar
• Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998;58:3307–11.
   PubMed Web of Science ®Google Scholar